LGND · Ligand Pharmaceuticals Inc
$296.34
+8.33 (+2.89%)
At close · Jul 30
Market Cap
$5.86B
Shares
20.04M
Ligand Pharmaceuticals Inc Earnings Call Transcripts
Every quarterly earnings call for Ligand Pharmaceuticals Inc (LGND) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲1.9%
$66.09M
$404,000
'22 Q3
22-11-07
▼10.7%
$50.38M
−$17.48M
'22 Q4
23-02-22
▼3.8%
$43.98M
$41.95M
'23 Q1
23-05-04
▼54.1%
$26.37M
$2.29M
'23 Q2
23-08-08
▼50.3%
$32.87M
−$10.27M
'23 Q3
23-11-08
▼44.2%
$28.10M
$18.19M
'23 Q4
24-02-27
▼29.6%
$30.98M
$86.14M
'24 Q1
24-05-07
▲57.5%
$41.53M
−$51.91M
'24 Q2
24-08-06
▲57.6%
$51.81M
−$7.17M
'24 Q3
24-11-07
▲52.4%
$42.81M
−$31.09M
'24 Q4
25-02-27
▲46.3%
$45.33M
−$42.45M
'25 Q1
25-05-08
▲14.7%
$47.63M
$4.85M
'25 Q2
25-08-07
▲122.8%
$115.46M
$117.27M
'25 Q3
25-11-06
▲39.4%
$59.67M
$44.78M
'25 Q4
26-02-26
LATEST
▲14.1%
$51.72M
−$13.35M
'26 Q1
26-05-07
Earnings call
FY26 · Q2
2026-08-06
Ligand Second Quarter 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Ligand Pharmaceuticals Inc Q1 FY2026 Earnings Call
Confident tone
Filspari (sparsentan) franchise
Pelvella Qtorin rapamycin (MLM)
Investor day and long-term outlook
Revenue
$51.72M
▲ 14.1% YoY Diluted EPS
$-0.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-25
Nordic-American Healthcare Conference 2026
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-23
38th Annual ROTH Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-11
Leerink Partners Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-26
Ligand Pharmaceuticals Inc Q4 FY2025 Earnings Call
Confident tone
FILSPARI FSGS and IgAN market opportunity
Royalty portfolio growth and key products
Pelvella/SELVA trial and QTORIN rapamycin
Revenue
$59.67M*
▲ 39.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-02-25
Oppenheimer 36th Annual Healthcare Life Sciences Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-06
Ligand Pharmaceuticals Inc Q3 FY2025 Earnings Call
Confident tone
ZELSUVMI / Pelthos launch
Product launches (Ohtuvayre, FILSPARI, CAPVAXIVE)
Development-stage pipeline (Palvella, AT292)
Revenue
$115.46M
▲ 122.8% YoY Diluted EPS
$5.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Ligand Pharmaceuticals Inc Q2 FY2025 Earnings Call
Confident tone
O2vir / Verona / Merck acquisition
Pelthos / Zelsuvmi launch and value creation
Pipeline catalysts (Filspari, Agenus, Alda, Qarziba)
Revenue
$47.63M
▲ 14.7% YoY Diluted EPS
$0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Ligand Pharmaceuticals Inc Q1 FY2025 Earnings Call
Confident tone
Commercial product launches (Ohtuvayre, Capvaxive, Zelsuvmi)
Filspari label expansion and FSGS sNDA
NITRICIL platform and special situations
Revenue
$45.33M
▲ 46.3% YoY Diluted EPS
$-2.21
▼ 146.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Ligand Pharmaceuticals Inc Q4 FY2024 Earnings Call
Confident tone
Castle Creek / D-Fi investment
Business development pipeline and opportunity set
Zelsuvmi / Pelthos launch and partnership search
Revenue
$42.81M*
▲ 52.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Ligand Pharmaceuticals Inc Q3 FY2024 Earnings Call
Confident tone
Travere FILSPARI
Ohtuvayre and CAPVAXIVE launches
Revenue growth and guidance
Revenue
$51.81M
▲ 57.6% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Ligand Pharmaceuticals Inc Q2 FY2024 Earnings Call
Confident tone
Royalty Portfolio Expansion
Investment Activity and Capital Deployment
Captisol Business Review
Revenue
$41.53M
▲ 57.5% YoY Diluted EPS
$-2.88
▼ 2315.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ligand Pharmaceuticals Inc Q1 FY2024 Earnings Call
Confident tone
Partnered pipeline catalysts
Royalty aggregation and investment strategy
Zelsuvmi and Pelthos Therapeutics
Revenue
$30.98M
▼ 29.6% YoY Diluted EPS
$4.75
▲ 103.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Ligand Pharmaceuticals Inc Q4 FY2023 Earnings Call
Confident tone
Approved Products and Commercial Catalysts
Pipeline PDUFA Approvals
Teriparatide and Competitive Risks
Revenue
$28.10M*
▼ 44.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Ligand Pharmaceuticals Inc Q3 FY2023 Earnings Call
Revenue
$32.87M
▼ 50.3% YoY Diluted EPS
$-0.59
▼ 3050% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Ligand Pharmaceuticals Inc Q2 FY2023 Earnings Call
Revenue
$26.37M
▼ 54.1% YoY Diluted EPS
$0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Ligand Pharmaceuticals Inc Q1 FY2023 Earnings Call
Revenue
$43.98M
▼ 3.8% YoY Diluted EPS
$2.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Ligand Pharmaceuticals Inc Q4 FY2022 Earnings Call
Revenue
$50.38M
▼ 10.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Ligand Pharmaceuticals Inc Q3 FY2022 Earnings Call
Revenue
$66.09M
▲ 1.9% YoY Diluted EPS
$0.02
▼ 96% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ligand Pharmaceuticals Inc Q2 FY2022 Earnings Call
Revenue
$57.42M
▼ 32.2% YoY Diluted EPS
$-0.03
▼ 102.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Ligand Pharmaceuticals Inc Q1 FY2022 Earnings Call
Revenue
$45.69M
▼ 17.1% YoY Diluted EPS
$-0.57
▼ 186.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Ligand Pharmaceuticals Inc Q4 FY2021 Earnings Call
Revenue
$56.40M
▼ 19.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Ligand Pharmaceuticals Inc Q3 FY2021 Earnings Call
Revenue
$64.83M
▲ 54.9% YoY Diluted EPS
$0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Ligand Pharmaceuticals Inc Q2 FY2021 Earnings Call
Revenue
$84.67M
▲ 104.4% YoY Diluted EPS
$1.12
▲ 35.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-03
Ligand Pharmaceuticals Inc Q1 FY2021 Earnings Call
Revenue
$55.15M
▲ 66.3% YoY Diluted EPS
$0.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Ligand Pharmaceuticals Inc Q4 FY2020 Earnings Call
Revenue
$69.99M
▲ 159.2% YoY Diluted EPS
$0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-30
Ligand Pharmaceuticals Inc Q3 FY2020 Earnings Call
Revenue
$41.85M
▲ 68.7% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-03
Ligand Pharmaceuticals Inc Q2 FY2020 Earnings Call
Revenue
$41.42M
▲ 65.8% YoY Diluted EPS
$0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ligand Pharmaceuticals Inc Q1 FY2020 Earnings Call
Revenue
$33.16M
▼ 23.7% YoY Diluted EPS
$-0.91
▼ 104.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Ligand Pharmaceuticals Inc Q4 FY2019 Earnings Call
Revenue
$27.00M
▼ 54.7% YoY Diluted EPS
$-0.27
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 earnings calls
Key facts
CIK
886163
CUSIP
53220K504
13F (30d)
117 filings
114 filers
Visit website
Investor relations